103 related articles for article (PubMed ID: 9661877)
1. Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection.
Bulfone-Paus S; von Bernuth H; Rückert R; Wachtlin J; Ungureanu D; Notter M; Krause H; Pohl T; Paus R; Kunzendorf U
Cancer Res; 1998 Jul; 58(13):2707-10. PubMed ID: 9661877
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
Zier KS; Salvadori S; Cronin KC; Gansbacher B
Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
4. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant.
Hock H; Dorsch M; Kunzendorf U; Uberla K; Qin Z; Diamantstein T; Blankenstein T
Cancer Res; 1993 Feb; 53(4):714-6. PubMed ID: 7679048
[TBL] [Abstract][Full Text] [Related]
5. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
Yoshimura K; Hazama S; Iizuka N; Yoshino S; Yamamoto K; Muraguchi M; Ohmoto Y; Noma T; Oka M
Cancer Gene Ther; 2001 Jan; 8(1):9-16. PubMed ID: 11219497
[TBL] [Abstract][Full Text] [Related]
6. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
[TBL] [Abstract][Full Text] [Related]
7. Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein.
Budagian V; Nanni P; Lollini PL; Musiani P; Di Carlo E; Bulanova E; Paus R; Bulfone-Paus S
Scand J Immunol; 2002 May; 55(5):484-92. PubMed ID: 11975760
[TBL] [Abstract][Full Text] [Related]
8. Functional defects are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells.
Salvadori S; Gansbacher B; Zier K
Cancer Gene Ther; 1994 Sep; 1(3):165-70. PubMed ID: 7542552
[TBL] [Abstract][Full Text] [Related]
9. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.
Qin Z; Blankenstein T
Cancer Res; 1995 Nov; 55(21):4747-51. PubMed ID: 7585497
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
[TBL] [Abstract][Full Text] [Related]
13. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy of plasmacytoma: comparison of the therapeutic efficacy of tumour cells transduced with the interleukin-2, interleukin-4, or interleukin-6 genes.
Bubeník J; Símová J; Zeuthen J; Diamant M; Jandlová T; Bubeníková D
Folia Biol (Praha); 1994; 40(1-2):29-36. PubMed ID: 7958062
[TBL] [Abstract][Full Text] [Related]
15. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
16. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
Wright P; Zheng C; Moyana T; Xiang J
Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
[TBL] [Abstract][Full Text] [Related]
18. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
19. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity.
Chang Y; Prud'homme GJ
J Gene Med; 1999; 1(6):415-23. PubMed ID: 10753067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
